Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$505.7 million.
- Kymera Therapeutics' Enterprise Value rose 805.28% to -$505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$505.7 million, marking a year-over-year increase of 805.28%. This contributed to the annual value of -$488.7 million for FY2024, which is 3037.31% down from last year.
- Kymera Therapeutics' Enterprise Value amounted to -$505.7 million in Q3 2025, which was up 805.28% from -$665.4 million recorded in Q2 2025.
- Kymera Therapeutics' 5-year Enterprise Value high stood at -$333.5 million for Q1 2021, and its period low was -$709.0 million during Q1 2025.
- Its 5-year average for Enterprise Value is -$464.2 million, with a median of -$442.4 million in 2021.
- Per our database at Business Quant, Kymera Therapeutics' Enterprise Value plummeted by 48898.0% in 2021 and then soared by 2574.83% in 2023.
- Quarter analysis of 5 years shows Kymera Therapeutics' Enterprise Value stood at -$442.4 million in 2021, then increased by 7.97% to -$407.2 million in 2022, then rose by 7.93% to -$374.9 million in 2023, then crashed by 30.37% to -$488.7 million in 2024, then dropped by 3.47% to -$505.7 million in 2025.
- Its Enterprise Value stands at -$505.7 million for Q3 2025, versus -$665.4 million for Q2 2025 and -$709.0 million for Q1 2025.